Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term PHASE-III TRIAL. Found 10 abstracts

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network. 2014 May;12(5):686-718.   PMCID: No NIH funding
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31. Journal of Clinical Oncology. 2009 Jan;27(1):92-9.   PMCID: PMC2645096
Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets. 2009 Mar;13(3):339-62.   PMCID: PMC2670612
Tian CQ, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK, Gynecologic Oncology Grp Study; Gynecologic Oncology Grp S. CA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers A Gynecologic Oncology Group Study. Cancer. 2009 Apr;115(7):1395-403.   PMCID: PMC 2743569
Zorn KK, Tian CQ, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK. The Prognostic Value of Pretreatment CA 125 in Patients With Advanced Ovarian Carcinoma A Gynecologic Oncology Group Study. Cancer. 2009 Mar;115(5):1028-35.   PMCID: PMC 2664510
Chan JK, Tian CQ, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC. Prognostic factors for high-risk early-stage epithelial ovarian cancer - A Gynecologic oncology group study. Cancer. 2008 May;112(10):2202-10.
Simon GR. Individualizing Chemotherapy for Non-small Cell Lung Cancer (NSCLC) in the Adjuvant and Advanced Setting: Current Status and Future Directions. Current treatment options in oncology. 2008 Dec;9(4-6):300-12.
Bruner DW, Barsevick A, Tian C, Randall M, Mannel R, Cohn DE, Sorosky J, Spirtos NM. Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study. Quality of Life Research. 2007 Feb;16(1):89-100.
Devlin JG, Langer CJ. Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: A retrospective review of the Fox Chase Cancer Center experience and a review of the literature. Clinical lung cancer. 2007 Mar;8(5):319-26.
Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D. Treatment of non-small cell lung cancer, stage IV - ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3):277S-289S.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term PHASE-III TRIAL

PHASE-III TRIAL ELDERLY-PATIENTS INTRAPERITONEAL CISPLATIN RANDOMIZED-TRIAL QUALITY-OF-LIFE STAGE-III PACLITAXEL ANDROGEN DEPRIVATION STANDARD ACUTE MYELOID-LEUKEMIA PREFERENCES CELL LUNG-CANCER progression-free survival tyrosine kinase inhibitor TYROSINE KINASE INHIBITORS THERAPY BODY-COMPOSITION neurotoxicity SUPPORTIVE EXCISION-REPAIR CA-125 Group METASTATIC COLORECTAL-CANCER MESSENGER-RNA EXPRESSION PLATINUM INTRAOPERATIVE RUPTURE PROTEIN-INTERACTION DOSE-RATE BRACHYTHERAPY ERCC1 EXPRESSION epithelial ovarian cancer erlotinib chemotherapy resistance STAGE REPRODUCTIVE AGE-GROUP therapy BREAST-CANCER cetuximab clear cell cancer CA-125-mucinous cell cancer-ovarian cancer HORMONE AGONISTS ABC transporter PERIPHERAL NEUROPATHY DATA-BASE REPORT SINGLE-AGENT GEMCITABINE SINGLE-AGENT VINORELBINE NATIONAL SURVEY PRETREATMENT CA-125 METALLOPROTEINASE INHIBITOR BMS-275291 SUPPRESSION LEUKEMIA GROUP-B PLATINUM-BASED CHEMOTHERAPY network CARCINOMA early-stage ovarian cancer-prognosis-survival RADIATION-THERAPY health behavior MEN ANTIGEN 3-DIMENSIONAL CONFORMAL IN-VITRO non-small cell lung cancer chemotherapy-quality of life-targeted therapy EGFR ASSISTED MULTIVARIATE-ANALYSIS third-line GENE COPY NUMBER DRUG-RESISTANCE MONOCLONAL-ANTIBODY PELVIC RADIOTHERAPY CLINICAL-SIGNIFICANCE CARBOPLATIN PREOPERATIVE CA-125 GROWTH-FACTOR-RECEPTOR COMPETING RISK CHEMOTHERAPY REGIMENS CISPLATIN PLUS GEMCITABINE INTERNATIONAL-FEDERATION DOCETAXEL RIBONUCLEOTIDE REDUCTASE EXTERNAL-BEAM RADIOTHERAPY GROUP EXPERIENCE DOXORUBICIN SYNDROME INTENSITY-MODULATED psychological RANDOMIZED CONTROLLED-TRIAL endometrial cancer COGNITIVE-BEHAVIOR THERAPY RADIOTHERAPY PROGNOSTIC-FACTORS STEREOTACTIC BODY RADIOTHERAPY VINORELBINE PLUS CISPLATIN antibody LAPAROSCOPIC PROSTATECTOMY Oncology INTRAVENOUS CISPLATIN PLUS NEUROTOXICITY VINDESINE PLUS CISPLATIN Gynecologic Oncology PERMANENT INTERSTITIAL BRACHYTHERAPY CARE SURVIVAL CISPLATIN CHEMOTHERAPY ORAL VINORELBINE CANCER-PATIENTS CA 125 tumor marker ADJUVANT TREATMENT CANCER METABOLIC ardaptation COOPERATIVE-ONCOLOGY-GROUP SUPPORTIVE CARE NETWORK fourth-line therapy second-line therapy CHEMOSENSITIVITY DEFINITIVE RADIOTHERAPY
Last updated on Friday, June 05, 2020